CAC 40
8 017,74 +21,10 (+0,26 %) Euro Stoxx 50
4 980,00 +23,04 (+0,46 %) Dow Jones
38 852,27 +176,59 (+0,46 %) EUR/USD
1,0767 -0,0007 (-0,06 %) Gold future
2 325,00 -6,20 (-0,27 %) Bitcoin EUR
59 706,87 -1 037,99 (-1,71 %)
Kyowa Kirin Co., Ltd. (KYKOF)
Kyowa Kirin Co., Ltd.
Otemachi Financial City Grand Cube
1-9-2, Otemachi Chiyoda-ku
Tokyo 100-0004
Japan
81 3 5205 7200
https://www.kyowakirin.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 5 974
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Masashi Miyamoto Ph.D. | President, CEO & Representative Director | 833,41k | S.O. | 1959 |
| Mr. Motohiko Kawaguchi | CFO, Managing Executive Officer & Head of Global Finance | S.O. | S.O. | S.O. |
| Mr. Yutaka Osawa M.B.A. | CCO, Executive VP & Representative Director | 507,86k | S.O. | 1959 |
| Kazuki Nemoto | Head of Global Legal | S.O. | S.O. | S.O. |
| Hiroki Nakamura | Global Corporate Communications Head | S.O. | S.O. | S.O. |
| Hiroshi Sonekawa | Managing Executive Officer, VP and Head of Sales & Marketing Division | S.O. | S.O. | S.O. |
| Wataru Murata M.B.A. | Chief People Officer & Head of Global Human Resources | S.O. | S.O. | S.O. |
| Mr. Takeyoshi Yamashita Ph.D. | Chief Medical Officer, Senior Managing Executive Officer & Director | S.O. | S.O. | 1961 |
| Yasuo Fujii M.B.A. | Chief Strategy Officer, VP & Managing Executive Officer | S.O. | S.O. | S.O. |
| Jean-David Rafizadeh-Kabe J.D., M.D. | Head of Global Operational Transformation | S.O. | S.O. | S.O. |
Description
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Kyowa Kirin Co., Ltd. en date du 1 mai 2024 est 1. Les scores principaux sont Audit : 1; Société : 1; Droits des actionnaires : 4; Compensation : 1.
